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Abstract
Background: Cytokines released from adipose tissues induce chronic low-grade inflammation, which may enhance
cancer development. We investigated whether indices of obesity and circulating adipokine levels could predict
incident cancer risk.
Materials and Methods: This longitudinal community-based study included subjects from the Hong Kong
Cardiovascular Risk Factors Prevalence Study (CRISPS) study commenced in 1995-1996 (CRISP-1) with baseline
assessments including indices of obesity. Subjects were reassessed in 2000-2004 (CRISPS-2) with measurement of
serum levels of adipokines including interleukin-6 (IL-6), soluble tumor necrosis factor receptor 2 (sTNFR2; as a
surrogate marker of tumor necrosis factor-α activity), leptin, lipocalin 2, adiponectin and adipocyte-fatty acid binding
protein (A-FABP). Incident cancer cases were identified up to 31 December 2011.
Results: 205 of 2893 subjects recruited at CRISPS-1 had developed incident cancers. More of the subjects who
developed cancers were obese (22.1 vs 16.1%) or had central obesity (36.6 vs 24.5%) according to Asian cut-offs.
Waist circumference (adjusted HR 1.02 [1.00-1.03] per cm; p=0.013), but not body mass index (adjusted HR 1.04
[1.00-1.08] per kg/m2; p=0.063), was a significant independent predictor for incident cancers after adjustment for age,
sex and smoking status. 99 of 1899 subjects reassessed at CRISPS-2 had developed cancers. Subjects who
developed cancers had significantly higher level of hsCRP, IL-6, sTNFR2 and lipocalin 2. After adjustment for
conventional risk factors, only IL-6 (HR 1.51, 95% CI 1.18-1.95) and sTNFR2 (HR 3.27, 95%CI 1.65-6.47) predicted
cancer development.
Conclusions: Our data supported the increased risk of malignancy by chronic low grade inflammation related to
central obesity.
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Introduction
The prevalence of obesity has increased dramatically in the
last three decades globally[1]. In a World Health Organization
report, over 400 million people were estimated to be obese in
2005, and by 2015, the figure will rise to over 700 million[2].
Cardiometabolic disorders related to obesity, including type 2
diabetes, hypertension, dyslipidemia, ischemic heart disease
and stroke, cause premature mortality and pose a serious
challenge to the modern health care system[1]. In recent years,
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the association of obesity, in particular central obesity, with
cancers has been increasingly recognized[3]. Obesity is
associated with adipose tissue inflammation[4] and an
increased production of the pro-inflammatory adiopkines such
as leptin, interleukin-6(IL-6) and tumor necrosis factor-alpha
(TNF-α), lipocalin 2 and adipocyte fatty acid binding protein (A-
FABP) which have been shown to enhance tumorigenesis in
different tumor cell line models and animal based
studies[5,6,7,8] . On the other hand, adiponectin, an anti-
inflammatory adipokines with reduced expression in obesity,
may be protective against the development of cancers such as
breast, endometrial and colorectal cancers[9] . In humans,
prospective epidemiological studies have also reported the
association of high levels of interleukin-6(IL-6), tumor necrosis
factor-alpha (TNF-α) and A-FABP[10,11,12,13], and low level
of adiponectin[9], with cancer development. Whether the
proinflammatory adipokines are associated with cancer
development in the Chinese population, which has a lower
prevalence of obesity and different body fat distribution when
compared with Caucasians[14,15], remains unclear. In this
study, the role of body adiposity and circulating levels of pro-
inflammatory adipokines as predictors of incident cancers was
addressed in a population-based cohort of Hong Kong
Chinese.
Materials and Methods
Patients
The Hong Kong Cardiovascular Risk Factor Prevalence
Study (CRISP) Cohort.  The Hong Kong Cardiovascular Risk
Factor Prevalence Study Cohort (CRISP) is a population-based
prospective study on Chinese, mostly originated from Southern
China. The study commenced as a cross-sectional survey in
1995-1996 (CRISP1) [16] with subjects recruited from the
general population through random selections of telephone
numbers. After baseline assessment, subjects were invited for
prospective follow-up to assess the development of major
cardiovascular diseases and cancers with subsequent
assessments carried out in 2000-2004 (CRISPS2)[17].
Subjects attended all assessments at the Queen Mary Hospital
after an overnight fast. At each assessment, demographic data,
medical and drug histories, smoking and family histories of
cardiovascular diseases and diabetes were obtained using a
standardized questionnaire. Subjects were characterized for
anthropometric parameters as previously described [16,17]. At
CRISPS-2, plasma and serum samples were taken for the
measurement of biomarkers including adipokines. Diagnoses
of cancers, based on ICD-9
(140-165,170-176,179-209,230-239) and date of diagnosis
were verified from the Hong Kong Hospital Authority database,
with cut-off date of 31 December 2011. The prospective
relationship between incident cancers over 16 years and
obesity was assessed using baseline anthropometric
parameters measured in 1995-6 (CRISP1). On the other hand,
adipokine levels measured in 2000-4 (CRISP2) were used as
baseline data in examining the relationship between 9.5-year
cancer incidence and obesity-related adipokines. This study
was approved by the Institutional Review Board of the
University of Hong Kong / Hospital Authority Hong Kong West
Cluster, and all participants gave written informed consent.
Biochemical Measurements
Blood glucose, insulin and lipid levels were measured as
described [17,18]. T2DM was defined as fasting glucose
≥126mg/dl and/or 2-hour post-OGTT glucose ≥200mg/dl or
already on treatment. Dyslipidemia was defined as having one
or more of the following criteria: 1) fasting
triglyceride≥150mg/dl; 2) HDL-cholesterol <50mg/dl in females
and <40mg/dl in males; 3) LDL-cholesterol >130mg/dl and 4)
already on lipid-lowering drugs. HOMA-IR (homeostasis model
assessment index) was calculated as fasting glucose (in
mmol/L) times fasting insulin (in μIU/ml) divided by 22.5 [19].
High-sensitivity C-reactive protein (hsCRP) was measured with
a particle-enhanced immunoturbidimetric assay (Roche
Diagnostics, GmbH, Mannheim, Germany) using anti-CRP
mouse monoclonal antibodies coupled to latex microparticles.
Adiponectin and lipocalin 2 were measured with in-house
sandwich ELISA established in our laboratory [18,20]. The
other adipokines were measured using commercially available
ELISA assay kits- adipocyte-fatty acid binding protein(A-FABP)
and leptin: BioVendor Laboratory Medicine, Inc., Modrice,
Czech Republic; soluble tumor necrosis factor-alpha receptor-2
(sTNFR2),as a surrogate marker of TNF-α activity: R&D
System, Inc., Minneapolis, USA; IL-6: Bender MedSystems
GmbH, Vienna, Austria.
Statistical Methods
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS Version 16.0; SPSS
Inc, Chicago). Baseline variables were compared using chi-
square, partial correlation or analysis of variance as
appropriate. Variables were tested for normality using
Kolmogorox-Smirnov test, and skewed variables were natural-
logarithmically transformed before analysis. Biologically
relevant variables were entered into Cox proportional hazard
regression analyses by forced entry to identify the independent
predictors for incident cancers.
Results
Part I. Obesity-related Parameters and Incident Cancers
2895 subjects (1412 men and 1483 women) were recruited
at CRISPS-1. Two patients with known history of malignancy
were excluded. After a median follow-up of 16.0 years
(interquartile range 15.6-16.5 years), 205 patients had
developed cancers (Table S1 in File S1) with an incidence rate
of 4.62 per 1000 person-years. The commonest type of cancer
was carcinoma of the lung (44 subjects), followed by colorectal
cancer (36), breast cancer (20), prostate cancer (18) and
cancers of the female reproductive tract (14). The median time
for cancer development from baseline was 8.7 years
(interquartile range 4.9 to 13.2 years). Table 1 shows that,
compared to subjects with no incident cancer on follow up,
those who developed cancers were more likely to be male
(p=0.004), older (p<0.001), current or ex-smoker (p=0.001),
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have higher body mass index (p=0.002), higher waist
circumference (p<0.001, sex-adjusted), and hypertension
(systolic blood pressure ≥140 mmHg and/or diastolic blood
pressure ≥90 mmHg or on treatment[21]; p<0.001), type 2
diabetes ( p<0.001), and dyslipidemia (p=0.004) at baseline
(1995-6; CRISP1). There was no significant difference in
HOMA-IR (p=0.119), fasting insulin level (p=0.683) and alcohol
use (p=0.678). More of the subjects who developed cancers
were obese (p<0.001) or had central obesity (p<0.001)
according to Asian cut-offs (BMI≥27.5 kg/m2 for obesity and
WC≥90cm in male or 80cm in female for central obesity
[14,22]). If the general cut-off for obesity (BMI≥30 kg/m2) was
used, the prevalence of obesity was 8.3% and 6.1% (p=0.197)
for cancer and non-cancer group respectively. After adjustment
for potential confounding factors, including age, sex, smoking
status, WC (adjusted HR 1.02 [1.00-1.03] per cm increase in
WC; p=0.013), but not BMI (adjusted HR 1.04 [1.00-1.08] per
kg/m2 increase in BMI ; p=0.063), was found to be a significant
independent predictor for incident cancers (Table 2, Model 1
and Model 2). WC remained as an independent predictor when
diabetes status was also taken into consideration. (Model 3 of
Table 2; adjusted HR 1.02[1.00-1.03] per cm increase in WC;
p=0.019). Analyses were repeated according to estrogen
dependency of the tumor types (estrogen dependent tumors
included carcinoma of lung, colon, breast, prostate and female
reproductive tract[23], which comprised 132 of the 205 cancer
cases). WC, but not BMI, had a borderline association with
incident cancer after controlling for age, sex and smoking
status with or without DM (adjusted HR 1.02 [1.00-1.04];
p=0.067 with DM or HR 1.03[1.00-1.04]; p=0.066 without DM in
models).
Part II. Adipokines and Incident Cancers
1944 subjects returned for CRISPS2 (2000-4) assessment.
After excluding 45 subjects with known cancers or incomplete
data at CRISP-2, a total of 1899 (882 male and 1017 female)
subjects were included in the analysis. 99 had developed
cancers after a median follow up interval of 9.5 years
(interquartile range 8.8-10.3). Table 3 shows that, compared
with subjects with no cancer, those who developed cancers
were more likely to be male (p=0.007), older (p<0.001), current
or ex-smoker (p=0.03), have higher waist circumference
(p=0.014), and type 2 diabetes (p=0.003) and dyslipidemia
(p=0.044) at baseline (2000-4; CRISP2). There was no
difference in BMI (p=0.189), HOMA-IR (p=0.143), fasting
insulin level (p=0.323), proportion with hypertension (p=0.062)
and alcohol use (p=0.518).
Baseline biomarkers in 2000-4 (CRP, IL-6, sTNFR2, leptin,
lipocalin 2 and A-FABP) had significantly positive correlation
with indices of obesity WC and BMI while adiponectin had
significant negative correlation (Table 4). Table 5 shows that
subjects who developed cancers had a higher level of baseline
hsCRP (p<.001); IL-6 (p<0.001, sex-adjusted); sTNFR2
(p<0.001, sex-adjusted) and lipocalin 2 (p=0.027, sex-
adjusted). There was no difference between the two groups in
the level of adiponectin, leptin and A-FABP.
After adjustment for age, sex, and smoking status (Model 1
of Table 6), only baseline IL-6 and sTNFR2 remained to be
independent predictors for incident cancers with hazard ratio
(HR) of 1.51 (95% CI 1.18-1.95, p=0.001) per natural log unit
increase in IL-6, and 3.27 (95% CI 1.65-6.47, p=0.001) per
natural log unit increase in sTNFR2, respectively. Similar
conclusion was reached when WC and/or diabetes status were
also included as covariates (Model 2, 3 and 4 of Table 6).
Since tumors are possible sources for inflammatory cytokines
like IL-6 and TNF-α, analyses were repeated after excluding 8
patients who developed cancers within one year from baseline,
to reduce the effect of a preclinical malignancy. Similar results
were obtained with baseline IL-6 and sTNFR2 remaining as
independent predictors of incident cancers, with HR of 1.53
(1.18-2.00, p=0.002) per natural log unit increase in IL-6, and
3.15 (1.53-6.47, p=0.002) per natural log unit increase in
sTNFR2, respectively.
Discussion
There is now increasing evidence that obesity contributes to
the development of many cancers, including cancers of colon,
breast, liver, gall bladder, endometrium, kidney, prostate and
pancreas [24,25]. A 5 kg/m2 increase in body mass index (BMI)
above normal was found to increase the risk of developing
many types of cancers by 24 to 59% in both sexes [3]. Study in
Asia-Pacific region also showed a 5-unit increase in BMI above
18.5 kg/m2 raised all cancer-mortality by 1.09 times [26].
Although the prevalence of obesity has been shown to be lower
in Chinese populations when compared with Western
populations even when Asian-Pacific cut-offs for obesity are
Table 1. Baseline clinical characteristics of CRISPS-1
(1995-6) cohort subjects with and without incident cancers.
 Incident cancer No cancer p-value
N 205 2688 --
Sex (% Male) 120 (58.5%) 1290 (48.0%) 0.004
Age (years) 56±11.6 45±12.5 <0.001
Ever smoker (%) 73 (35.6%) 667 (24.9%) 0.001
Alcohol drinker (%) 73 (35.6%) 994 (37.1%) 0.678
Body Mass Index (kg/m2) 24.9±3.96 24.1±3.57 0.002
Obesity (%) 45 (22.1%) 432 (16.1%) 0.015
Waist Circumference (cm)   <0.001b
Male 86.6±10.2 82.7±9.45  
Female 78.6±9.08 75.0±9.35  
Central obesity (%) 75 (36.6%) 658 (24.5%) <0.001
Hypertension (%) 74 (36.1%) 449 (16.7%) <0.001
Diabetes (%) 36 (18.1%) 241 (9.4%) <0.001
HOMA-IRa,c 1.21 (0.79-2.11) 1.11 (0.72-1.79) 0.119
Fasting insulin (mIU/L) 5.10 (3.30-7.80) 4.90 (3.20-7.40) 0.683
Dyslipidemia (%) 151 (73.7%) 1707 (63.6%) 0.004
Data are expressed as mean±SD unless stated otherwise; a log-transformed
before analysis; b sex-adjusted p-value; c excluded 164 subjects with missing data;
obesity was defined as BMI ≥27.5kg/m2; central obesity was defined as WC>90
cm for men,>80cm for women; ever smoker was defined as current or former
smoker; alcohol drinker was defined as self-reported regular consumption of
alcohol.
doi: 10.1371/journal.pone.0078594.t001
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adopted [15], a rising trend, along with the incidence and
mortality of many cancers, is observed and is believed to be
related to the westernization of lifestyle[27]. Moreover, body fat
composition in Chinese is different from their Caucasian
counterparts and Chinese tend to have more central obesity,
and thus visceral fat, for a given BMI after adjustment for age
and sex [14]. Since the circulating levels of the pro-
inflammatory adipokines are higher in the portal vein than in
the peripheral arteries in obese subjects [28], visceral fat may
play a more important role in contributing to systemic
inflammation than the subcutaneous fat. In this Chinese
community cohort with a relative low prevalence of obesity
(16.5% and 6.2% having BMI ≥27.5 kg/m2 and BMI≥30 kg/m2
respectively), we demonstrated that waist circumference, an
indicator of central adiposity, but not BMI which represents
general obesity, was a significant independent predictor of
incident cancer development, even after adjusting for the effect
of age, the strongest risk factor in this cohort. This differential
effect of central and general adiposity on cancer risk has also
been demonstrated in other studies in the Asian-Pacific region.
In a case-control study of relatively lean Chinese population
with mean BMI 21.9 kg/m2, an increase in waist-hip ratio
increased the risk of prostate cancer by 3 folds while the risk
incurred by BMI was not significant[29]. Again, in a meta-
analysis of 30 cohort studies in Asian-Pacific region, WC but
not BMI, was associated with increased mortality from
pancreatic cancer[30].
Table 3. Baseline characteristics of CRISPS-2 (2000-4)
cohort subjects with and without incident cancers.
 Incident cancer No cancer p-value
N 99 1800 ---
Sex (% Men) 59 (59.6) 823 (45.7) 0.007
Age (years) 61.2±11.4 51.8±11.8 <0.001
BMI (kg/m2) 26.6±4.06 24.1±3.51 0.189
Waist circumference (cm)   0.014b
Men 86.2±9.50 84.2±9.06  
Women 79.0±9.22 76.2±9.10  
Ever smoker (%) 35 (35.4) 459 (25.5) 0.030
Alcohol drinker (%) 33 (33.3) 656 (36.5) 0.518
HOMA-IRa,c 1.85 (1.28-2.89) 1.66 (1.15-2.49) 0.143
Fasting insulin (mIU/L) 7.40 (5.60-11.0) 7.30 (5.20-10.5) 0.323
Diabetes (%) 26 (26.3) 267 (15.0) 0.003
Hypertension (%) 35 (35.4) 482 (26.8) 0.062
Dyslipidemia (%) 70 (70.7) 1089 (60.6) 0.044
Data are expressed as mean±SD unless stated otherwise; obesity was defined as
BMI ≥27.5kg/m2; central obesity was defined as WC>90 cm for men,>80cm for
women; a log-transformed before analysis; b sex-adjusted p-value; c excluded
n=99 subjects on diabetic treatment; Ever smoker was defined as current or former
smoker; Alcohol drinker was defined as self-reported regular consumption of
alcohol.
doi: 10.1371/journal.pone.0078594.t003
Table 2. Cox Proportional hazard regression showing that waist circumference, but not body mass index, independently
predicted cancer development.
 Model 1  Model 2  Model 3
Baseline parameters HR (95% CI) p-value  HR (95% CI) p-value  HR (95% CI) p-value
Men 1.21 (0.86-1.69) 0.272  1.36 (0.98-1.89) 0.065  1.34 (0.97-1.86) 0.080
Age (years) 1.07 (1.06-1.08) <0.001  1.07 (1.06-1.08) <0.001  1.07 (1.06-1.08) <0.001
WC (cm) 1.02 (1.00-1.03) 0.013  -- --  1.02(1.00-1.03) 0.019
BMI (kg/m2) -- --  1.04 (1.00-1.08) 0.063  -- --
Diabetes -- --  -- --  1.20 (0.85-1.68) 0.300
Ever smoker 1.20 (0.86-1.68) 0.295  1.20 (0.86-1.68) 0.287  1.05 (0.96-1.15) 0.313
Ever smoker was defined as current or former smoker; WC, waist circumference; BMI, body mass index.
doi: 10.1371/journal.pone.0078594.t002
Table 6. Cox proportional hazard regression models showing baseline IL-6 and sTNFR2 independently predicted incident
cancers.
 Model 1  Model 2  Model 3  Model 4
 (Base Model b)  (Base Model + WC)  (Base Model + Diabetes)  (Base Model + WC +Diabetes)
Baseline parameters HR (95% CI) p-value  HR (95% CI) p-value  HR (95% CI) p-value  HR (95% CI) p-value
CRP, per mg/La 1.20 (0.99-1.44) 0.062  1.17 (0.96-1.42) 0.124  1.19 (0.98-1.43) 0.073  1.17 (0.96-1.42) 0.127
IL-6, per pg/mla 1.51 (1.18-1.95) 0.001  1.49 (1.15-1.91) 0.002  1.52 (1.18-1.96) 0.001  1.50 (1.16-1.94) 0.002
sTNFR2, per ng/mla 3.27 (1.65-6.47) 0.001  3.21 (1.61-6.39) 0.001  3.20 (1.62-6.29) 0.001  3.16 (1.59-6.25) 0.001
Lipocalin 2, per ng/ml 1.23 (0.79-1.93) 0.363  1.21 (0.77-1.90) 0.401  1.23 (0.78-1.93) 0.367  1.22 (0.77-1.91) 0.397
a Log-transformed before analysis; b Base Model adjusted for age, sex and smoking status.
doi: 10.1371/journal.pone.0078594.t006
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Pro-inflammatory adipokines have been shown in vitro to
play significant pathophysiological roles in different stages of
tumorigenesis including cancer cell proliferation, angiogenesis
and metastasis [6,31] . Apart from their direct effects,
adipokines may also interact with sex hormones, sex-hormone
binding globulin, insulin-like growth factor or the binding
proteins to mediate the development of obesity-related cancers
[32]. In this study, we demonstrated the significant correlations
between indices of obesity and the baseline levels of pro-
Table 4. Partial correlations between baseline obesity
parameters and adipokines of CRISPS-2 (2000-4) cohort
subjects.
Biomarkers BMI WC
 Sex-adjusted r p-value Sex-adjusted r p-value
CRP 0.38 <0.001 0.37 <0.001
IL-6 0.16 <0.001 0.17 <0.001
sTNFR2 0.11 <0.001 0.17 <0.001
Adiponectin -0.33 <0.001 -0.30 <0.001
Leptin 0.60 <0.001 0.58 <0.001
Lipocalin 2 0.06 0.009 0.11 <0.001
A-FABP 0.43 <0.001 0.46 <0.001
All biomarkers were log-transformed before analysis.
doi: 10.1371/journal.pone.0078594.t004
Table 5. Baseline biomarkers of CRISPS-2 (2000-4) cohort
subjects with and without incident cancers.
 Incident cancer No cancer p-value
N 99 1800 ---
Biomarkers    
CRP (mg/L) 0.98 (0.50-1.99) 0.72 (0.33-1.55) 0.001
IL-6 (pg/ml)   <0.001
Men 0.76 (0.53-1.06) 0.58 (0.36-0.89)  
Women 0.65 (0.38-0.98) 0.54 (0.36-0.81)  
sTNFR2 (ng/mL)   <0.001
Men 2411.0 (1980.4-2752.6) 1990.4 (1700.1-2368.2)  
Women 2052.4 (1817.2-2787.0) 1815.2 (1562.3-2147.8)  
Adiponectin (mg/ml)   0.150
Men 5.88 (4.41-9.15) 5.50 (3.57-8.61)  
Women 7.90 (4.59-11.92) 7.82 (5.36-11.59)  
Leptin (ng/ml)   0.129
Men 5.50 (2.19-8.76) 4.53 (2.25-7.06)  
Women 13.66 (8.23-21.98) 11.40 (7.98-16.76)  
Lipocalin 2 (ng/ml)   0.027
Men 39.04 (30.14-51.73) 37.58 (30.41-47.53)  
Women 34.23 (26.64-57.18) 31.47 (25.32-40.18)  
A-FABP (ng/ml)   0.076
Men 20.90 (15.17-26.66) 19.15(14.09-25.90)  
Women 27.49 (19.14-41.33) 24.24 (17.41-33.36)  
Data are expressed as mean±SD unless stated otherwise; all biomarkers were log-
transformed before analysis; all sex-adjusted p-value except for CRP.
doi: 10.1371/journal.pone.0078594.t005
inflammatory markers, among which IL-6 and sTNFR2
independently predicted incident cancer development.
IL-6 and TNF-α are key cytokines involved in inflammation
and immunity [33,34]. Both of them had been shown in vitro to
be the links between chronic inflammatory states and cancers,
by promoting cell proliferation, enhancing angiogenesis and
cancer cell metastasis[35,36]. Epidemiological data also
supported the role of IL-6 and TNF-α in cancer promotion. In a
nested case-control study of 1298 postmenopausal women in
the United States, Ho GY et al. demonstrated that subjects with
IL-6 in highest quartile had a relative risk of 1.41 of developing
colorectal cancer though the association was insignificant after
adjustment for baseline insulin level[10]. Heikkila K et al. also
showed IL-6 was associated with increased lung and breast
cancer risks in a meta-analysis of two prospective cohorts, the
British Women’s Heart and Health study and the Caerphilly
Cohort[11]. In addition, in a sub-group analysis of the Nurses’
Health Study, Chan et al. showed that the relative risk of
development colorectal cancer was 1.67(95% CI 1.05-268,
p=0.03) in participants with highest quartile of sTNFR-2 level,
when compared with those in the lowest quartile[12]. While our
study was the first prospective study examining the effects of
the adipokines on cancer development in Chinese population,
our findings on IL-6 and sTNFR-2 were in line with those of
western cohorts.
Smoking, a well known carcinogenic risk factor, has been
associated with level of both IL6 and TNF-α[37,38]. In the
current study, smoking was more prevalent at baseline among
those who subsequently developed cancers. In the multivariate
analysis, however, smoking was not a significant independent
risk factor of cancer development, possibly suggesting that the
effect of smoking on cancer development is, at least in part,
mediated by these proinflammatory cytokines.
The negative findings on adiponectin in this study was
unexpected as this anti-inflammatory adipokine inhibited the
growth of several breast cancer cell lines in vitro [39]. In
epidemiological studies, hypoadiponectinemia had been shown
to predict the development of breast, endometrial, colonic,
renal cell carcinoma and many hematological malignancies [9].
The association between adiponectin and prostate or lung
cancers, on the other hand, was less consistent [40,41]. This
might explain why adiponectin did not emerge as a protective
factor in our cohort as prostate and lung cancers constituted a
significant proportion of our cancer cases.
This study has several limitations. Firstly, in view of the
relatively small numbers of incident cancer cases, the findings
of this study should be validated in studies involving larger
sample size. Secondly, since baseline assessments were
performed more than a decade ago and the list of adipokines is
growing, not all adipokines were measured in this study.
Thirdly, estradiol and its metabolites might be other important
confounding factors which were not measured. Numerous
studies have demonstrated the effects of estrogens on the
development and progression of different cancers[23] and
estrogen production in obesity state will be increased by
peripheral aromatization in the adipose tissues. However, our
subgroup analyses on obesity parameters and estrogen
dependent cancers were limited by small numbers of events,
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resulting in insignificant power to make a definitive conclusion.
Nonetheless, levels of CRP, IL-6, sTNFR2 were found to be
higher in subjects with low estrogen levels (post-menopausal
females, defined as women aged older than 55, and male
subjects) when compared to female subjects aged less than 55
with presumably higher estrogen levels (Table S2 in File S1).
Previous studies have also reported a suppressive effect of
estrogen on both adipokines in high levels, and at low levels,
no effect on IL-6 but stimulatory effect on TNF- α secretion[42].
In obesity, the increased estrogen production by the adipose
tissue would be tend to lower the secretion of these adipokines
and hence their effect on cancer development. Fourthly, other
factors which may impact on cancer development such as
family history of malignancy, lifestyle factors like dietary factors
and physical activity, and personal history of chronic
inflammatory diseases, were not included in the analyses.
Furthermore, detailed data on concomitant medications which
may impact on inflammation or adipokines levels, such as
aspirin, statins, blockers of the renin-angiotensin system and
thiazolidinediones, were not recorded. Finally, due to the
limitation of an observational study design, our findings could
only imply association but not causal relationship, though
multiple molecular mechanisms have been identified to link
cancer development with elevated cytokines in chronic
inflammatory states.
Conclusions
In conclusion, we have demonstrated in a population-based
study that high waist circumference, and raised serum levels of
the pro-inflammatory adipokines, IL-6 and TNFR2, can predict
the development of cancers in a Chinese cohort with relatively
low obesity prevalence. These associations are supportive of
the role of chronic low grade inflammation, related to central
obesity, in the development of cancers even though a causal
relationship cannot be concluded. When more epidemiological
data become available and with a better understanding of the
roles of these adipokines in tumourigenesis, risk models can be
constructed to identify high risk patients for the development of
malignancy so that appropriate measures may be employed to
reduce their risks. On the other hand, in patients with
established malignancy, the inflammatory cytokines level may
act as novel prognostic factors. Furthermore, the inhibition of
the inflammatory cytokines provides potential new strategies
for the treatment of cancers or for sensitizing tumors to
chemotherapeutic agents. While IL-6 and TNF-alpha receptor
antagonists are now used clinically for the treatment of a wide
range of rheumatological or hematological disorders, it will be
of interest to follow-up on patients treated with such agents for
any potential beneficial effects on cancer development.
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